Background Estimates of the economic impact of cardiovascular events in patients with type 2 diabetes are scarce. The aim of this study was to determine the health care costs associated with acute myocardial infarction (AMI) and stroke in patients with type 2 diabetes in Sweden. Design Population-based open cohort study of 9941 patients with type 2 diabetes retrospectively identified in primary care records at 26 centres in Uppsala County. Methods Episodes of AMI and stroke suffered by study patients were tracked in the Swedish National Inpatient Register. Annual per patient costs of health care were computed for the years 2000-2004 using register data covering inpatient care, outpatient hospital care, primary care and drugs. Panel data regression was applied to determine the impact of suffering a first or repeat AMI or stroke on health care costs during the year of the event and in subsequent years. Results Total health care costs of patients suffering a first AMI/stroke increased by 4.1/6.5 during the year of the event [95% confidence interval (CI): 3.1-5.4/4.9-8.5] and by 1.1/1.4 during subsequent years (95% CI: 1.0-1.3/1.2-1.6), controlling for age, sex, the event of amputation and presence of renal failure, heart failure and diabetic eye disease. Total health care costs of patients suffering a first or repeat AMI/stroke increased by 4.1/6.4 during the year of an event (95% CI: 3.2-5.2/5.0-8.1) but were not significantly higher during subsequent years. Conclusion Estimates of the costs related to major cardiovascular complications of type 2 diabetes are critical input to economic evaluations. Eur J Cardiovasc Prev Rehabil 16: [576][577][578][579][580][581][582] Costs were estimated at the per patient level by multiplying annual resource quantities incurred within primary care, outpatient hospital care, inpatient care, Costs of AMI and stroke in type 2 diabetes Ringborg et al. 577
Introduction
The presence of microvascular and macrovascular complications is strongly associated with costs in patients with type 2 diabetes [1] [2] [3] . Within the Cost of Diabetes in Europe -Type 2 (CODE-2) study, late-stage complications were found to be the single factor with the largest impact on costs [4] and a recent US estimate attributed 50% of diabetes-related medical expenditures to hospital inpatient care [5] .
Costs related to cardiovascular disease (CVD) seem to be particularly important [6, 7] . Compared with nondiabetic individuals, type 2 diabetic patients carry a substantially greater risk of suffering cardiovascular events [8, 9] and have been found to incur higher CVD-related costs once they develop the disease [10, 11] .
Estimates of the impact of CVD on costs in patients with type 2 diabetes are fundamental to economic evaluations of strategies to treat or prevent type 2 diabetes. These evaluations typically simulate the costs and clinical effectiveness associated with competing therapies and are increasingly called for by health care payers and reimbursement agencies, in particular for determining the extent to which increased costs of new therapies are offset by savings from lower rates of complications. Clarke et al. [12] have estimated the short-term and long-term costs associated with four diabetes-related cardiovascular complications (myocardial infarction, stroke, ischemic heart disease and heart failure) based on data from the United Kingdom Prospective Diabetes Study (UKPDS); and Gilmer et al. [13] have used medical claims data from a large US health plan to estimate the impact of coronary heart disease on costs, but for the Scandinavian countries, estimates of the costs associated with cardiovascular complications in type 2 diabetes have been lacking.
This study aimed to determine the immediate and longterm impact of acute myocardial infarction (AMI) and stroke on health care costs in patients with type 2 diabetes in Sweden using multivariate regression analysis of panel data for the years 2000-2004 from the Real-Life Effectiveness and Care Patterns in Diabetes Management (RECAP-DM) study. This was a population-based open cohort study of patients with type 2 diabetes retrospectively identified in primary care records in Uppsala County.
Methods

Patients and data
Details of the RECAP-DM study have been described earlier [14, 15] . Briefly, 26 public primary care centres serving 77% of the total population of Uppsala County (302 564 in 2004) participated in the study by granting access to computerized medical records kept from 1993 onwards. The study inclusion criteria for patients at the participating centres were records of at least one of the following three events in the primary care data available until 31 December 2004: (i) International Classification of Diseases (ICD) diagnostic code of diabetes type 2 (ICD-10 codes E11-E14; ICD-9 code 250); (ii) prescription of an oral glucose-lowering agent (ATC-code A10B) and (iii) fasting blood or plasma glucose value indicative of type 2 diabetes as defined in Swedish guidelines [before 1998: fasting blood glucose (FBG) Z 6.7 mmol/l; as of 1998: FBG Z 6.1 mmol/l or fasting plasma glucose Z 7.0 mmol/l] [16, 17] .
Patients with a single FBG or fasting plasma glucose value over cut-off and no diagnosis of type 2 diabetes at any time during the study period were excluded as were patients under 30 years of age at inclusion, patients under 40 years of age at inclusion who were prescribed insulin but not oral antidiabetic drug treatment and patients ever diagnosed with type 1 diabetes (ICD-10 code E10; ICD-9 codes 250.x1, 250.x3), diabetes because of underlying condition (ICD-10 code E08), drug or chemical-induced diabetes (ICD-10 code E09), gestational diabetes (ICD-10 code O24.4; ICD-9 code 648.8) or nonclinical diabetes (ICD-9 code 790.2).
The primary care data were extracted using the Pygargus CxP system (Pygargus AB, Stockholm, Sweden) and included a complete account of visits, consultations by phone, diagnoses, laboratory measurements and drug prescriptions recorded at the centres in association with patient contacts. Through linkage to the Swedish national personal identification numbers of identified patients, medical records data were additionally obtained from the outpatient clinics at Uppsala University Hospital (for the years 1993-2004), the National Inpatient Register (for the years 1987-2004) and the Swedish Registry for Active Treatment of Uremia (SRAU; for the years 1988-2004).
The outpatient clinic data obtained from Uppsala University Hospital (the main county hospital) were direct transcripts from the hospital patient administrative system in which diagnoses and operations recorded at patient visits are registered. The Inpatient Register is managed by the Swedish National Board of Health and Welfare, and provides patient, medical and administrative data on all hospitalizations in Sweden. Registration is mandatory with underreporting estimated to affect less than 2% of hospitalizations. As far as the SRAU is concerned, it includes records of all patients undergoing treatment (outpatient or inpatient) for renal failure.
Mortality data were obtained from the Causes of Death Register but were only available until the year 2003. The study was approved by the Regional Ethics Committee of Uppsala and all analyses were carried out using anonymous study identification numbers. A structured query language database was used to combine data from different sources.
Costs of health care
Earlier, we used the RECAP-DM database to estimate annual quantities of medical resource use of patients with type 2 diabetes for the years 2000-2004 and costs for the year 2004 [15] .
Currently, annual costs of health care were estimated for the years 2000-2004 for all prevalent cases of type 2 diabetes and the observations were subsequently merged to create a panel data set. Patients were counted as prevalent cases from the year of study inclusion until the year of their last record in the Uppsala County primary care records. Thus, patients included in the panel data set had a minimum of one and a maximum of five observations relating to medical resource use and costs, each referring to one calendar year between 2000 and 2004. drug treatment and dialysis by corresponding unit costs (reported in the study by Ringborg et al. [15] ) in year 2007 prices. All medical costs were considered, directly diabetes-related and nondiabetes-related.
Unit costs of caregiver contacts within primary care were obtained from a cost study conducted by the Swedish Aging Research Center [18] , whereas average unit costs of outpatient hospital visits, dialysis and inpatient care were obtained from the price list of Uppsala University Hospital [19] .
Costs of inpatient care were estimated using a cost per bed day approach. Data on the main diagnosis assigned to each hospitalization were used to determine the ward at which hospitalization was likely to have taken place according to the following: main diagnosis within ICD-10 chapter I: ward of Infectious Medicine; II: Oncology; III: Hematology; IV: Endocrinology and diabetes; V: Psychiatry; VI: Neurology; VII: Opthamology; VIII: Ear, Nose and Throat; IX: Cardiology; X: Pulmonary Medicine; XI: Gastroenterology; XII: Dermatology; XIII: Rheumatology; XIV: Renal Medicine/ Urology/Gynecology; XV: Obstetrics; XVIII: General Medicine; XIX: Orthopedics/General Surgery/General Medicine; XX: General Medicine and XXI: Rehabilitation. Costs of cardiac surgery were not included in bed day costs, and were thus estimated separately by assigning hospital unit costs to cardiac surgical procedures performed on study patients as recorded in the Inpatient Register.
Unit costs of drugs and devices for glucose monitoring and injection of insulin were obtained from the official national price list [20] . As generic substitution is mandatory in Swedish pharmacies since 2002, the lowest unit price within the prescribed ATC-category was applied. The analysis of drugs was restricted to antidiabetic (A10), anti-hypertensive (C03, C07, C08 and C09) and lipid-lowering (C10) drugs, and performed under the assumption that patients filled issued prescriptions. Costs were assigned on the date of prescription.
Predictors and confounding variables
For each year between 2000 and 2004, patients suffering an AMI or stroke were identified in the Inpatient Register according to the relevant ICD-10 codes (Table 1) , with first events distinguished from recurrent events.
In addition, to determine the long-term impact of CVD on health care costs, patients with a history of an AMI or stroke were identified for each year between 2000 and 2004, using ICD-9 and ICD-10 codes (Table 1) applied to the Inpatient Register data of 1987-2004. ICD-9 was used for inpatient care in Sweden until 1997 at which point it was replaced by ICD-10 in all counties except Skåne, which adopted ICD-10 in 1998.
The variables considered to confound the relationship between the event of an AMI/stroke and costs during a given year were: age, sex, amputation performed during the year and the presence of heart failure, diabetic eye disease (retinopathy or cataract) and/or renal failure, defined as any hospitalization or outpatient clinic visit in current or past years with heart failure, diabetic eye disease and/or renal failure, respectively, as a main or secondary diagnosis or, in the case of renal failure, any record of treatment for uraemia in the SRAU. The diagnostic and surgical procedures codes applied are reported in Table 1 .
Statistical analysis
We applied a population-averaged panel data regression model to estimate the immediate and long-term impact of AMI and stroke on health care costs controlling for age, sex, amputation and the presence of renal failure, heart failure and diabetic eye disease. This extension of the generalized linear model recognizes and accommodates the within-patient correlation between outcomes (in our case, health care costs) across the panel. An exchangeable correlation structure was applied and consistent with earlier research, the cost data were assumed to follow a g-distribution with a log link function. The general model was estimated as follows:
where Age was a continuous variable centred at the mean age of study patients (69 years); Sex was a categorical variable with female = 1 and male = 0; AMI and Stroke were indicator variables taking the value 1 if the patient suffered an AMI/stroke during the current year of observation; Post-AMI and Post-Stroke were indicator variables taking the value 1 during all years following the event of an AMI/stroke; Amputation was a categorical variable set to 1 if the patient suffered an amputation during the current year and Renal, Heart and Eye were categorical variables set to 1, if the patient had been diagnosed with chronic renal failure, heart failure and diabetic eye disease, respectively, at any prior hospitalization or outpatient clinic visit.
The dependent variable of the base-case model was total annual costs of health care defined as the sum of inpatient costs, outpatient costs (hospital and primary care), costs of drugs and costs of dialysis. Separate models were additionally run with inpatient costs and noninpatient costs as the dependent variable. We investigated the impact of a first AMI or stroke, and also the impact of any AMI or stroke (first or recurrent) on health care costs during the year of the event and during subsequent years. For first events, the indicator variables for AMI and Stroke only took the value 1 the year of the first event. While studying all events, these indicator variables were set to 1 if a first or recurrent event occurred during the year.
The multiplicative effect of each parameter on costs was obtained by exponentiating the model coefficient and was reported with 95% confidence interval (CI). As the age variable was centred (by subtracting the mean age from current age variable), it follows from Equation 1 that the exponent of the constant could be interpreted as the expected annual cost of 69-year-old male type 2 diabetic patients who did not suffer an AMI or stroke during the year and who had no history of either an AMI/stroke or of any of the other complications considered.
Results
A total of 9941 patients were identified as prevalent cases of type 2 diabetes between 2000 and 2004. Eighty-three percent of the patients (n = 8300) had a formal diagnosis of type 2 diabetes in the primary care records at some point during the study period and 60% (n = 5927) were prescribed an oral glucose-lowering agent. The mean (SD) age of patients was 69 (13) and 48% were female, which is similar to that of type 2 diabetic patients registered in the Swedish National Diabetes Register (mean age 67 years and 45% female in year 2003; n = 57 119) [21] .
The panel data set for the years 2000-2004 included 37 338 observations of annual health care costs, the mean number of observations per patient amounting to 3.8. There were 331 cases of a first AMI and 324 cases of a first stroke. When first and recurrent events were considered, the number of AMIs and strokes amounted to 450 and 435, respectively ( Table 2) .
During the period for which mortality data were available (years 2000-2003), 25% of patients suffering a first AMI (63 out of 248) and 22% of patients suffering a first stroke (55 out of 249) died during the year of the event.
The strong impact of an AMI or stroke on health care costs during the year of the event is shown in Table 3 , which reports the results of the panel data regression models. The first three columns refer to the models in which only first events were incorporated, whereas the last three columns refer to the models incorporating all events, first as well as recurrent. Suffering an AMI during a given year led to an expected 4.1-fold increase in total costs irrespective of whether the AMI was a first or recurrent event. Suffering a stroke during a given year lead to an expected 6.5-fold increase in total costs, if the stroke was a first-time event (95% CI: 4.9-8.5) and to a slightly lower 6.4-fold increase in total costs when all events were considered (95% CI: 5.0-8.1).
Clearly, the increase in costs associated with an AMI or stroke was largely accounted for by inpatient care. Expected inpatient costs during the year of a first AMI/ stroke were 6.3/11.4 times higher, whereas expected noninpatient costs were 1.5/1.3 times higher, the latter presumably accounted for by outpatient follow-up visits and prescription of drugs aimed at secondary prevention.
In the models incorporating first events alone, patients were found to incur somewhat higher costs during years following the event compared with patients without a history of an AMI or stroke. Total annual costs of patients in a post-AMI state were 1.1 times higher than those of event-free patients (95% CI: 1.0-1.3), whereas total annual costs of patients in a post-stroke state were 1.4 times higher (95% CI: 1.2-1.6). However, in the models incorporating all events, expected costs of patients in Costs of AMI and stroke in type 2 diabetes Ringborg et al. 579
post-AMI or post-stroke states were not found to be higher than patients without a history of these events. It thus seems as if the increased costs in years following a first AMI or stroke were accounted for by recurrent events, as the models incorporating all events effectively control for them.
Somewhat unexpectedly, predicted noninpatient costs among patients in the post-stroke state were found to be lower than noninpatient costs among patients without a history of the event. This finding is likely to be because of the fact that the noninpatient costs included by our study covered primary care, outpatient hospital care, drugs and dialysis but not institutional care. Patients who are institutionalized after having suffered a stroke are not likely to make visits to their primary care centre or outpatient hospital clinic and this is reflected in the negative coefficient of the Post-stroke variable. tions-free patient, equivalent to the case of all categorical variables for complications and comorbidities being set to 0, are additionally reported.
Discussion
This study has provided estimates of the impact of AMI and stroke on health care costs in Swedish patients with type 2 diabetes. The results confirm the substantial economic consequences of these two major cardiovascular events for health care payers. While the main patientlevel effect of an AMI or stroke in the immediate term was to raise inpatient costs, expected noninpatient costs during the year of an event were also higher. As far as the long-term economic impact is concerned, patients with a history of an AMI or stroke were found to have slightly higher health care costs than patients without a history of these events, a fact that seemed to be explained by recurring episodes of AMI and stroke.
Cost data related to major CVD complications are critical input to cost-effectiveness analyses of therapies in type 2 diabetes that are successful in reducing cardiovascular risk. Although estimates of the impact of AMI and stroke on health care costs have been lacking for patients with type 2 diabetes in Sweden, an earlier study has estimated costs of inpatient care, outpatient care and pharmaceuticals in non-diabetic patients hospitalized for coronary heart disease or stroke [22] . Total costs during the year of a first AMI or stroke were h6121 and h10 398, respectively, in 1994 prices compared with our estimates of h10 035 and h15 866 (2007 prices). The estimates from our study remained higher even when those reported by Zethraeus et al. [22] were inflated to the year 2007 price level (using the Swedish consumer price index [23] ), which most likely reflects the generally higher medical resource use of patients with type 2 diabetes.
In investigating the impact of AMI and stroke on health care costs in patients with type 2 diabetes, we used an approach very similar to that of UKPDS Study No. 65 that estimated the immediate and long-term costs of several diabetes-related complications using panel data from 5102 patients with type 2 diabetes [12] . Given the regular follow-up of patients within the UKPDS, episodes of AMI and stroke could be detected even if they did not lead to hospitalization, and health care costs were consequently determined using a two-part model, the first of which modelled the probability of being hospitalized given the occurrence of an event. Within the RECAP-DM study, only hospitalized cases of AMI and stroke could be tracked and all patients identified as suffering from these events thus incurred inpatient costs. Hence, panel data regression was applied directly. In contrast to our analysis, the UKPDS only investigated first events, and therefore we cannot infer whether the increased costs observed in years after an AMI or stroke were accounted for by recurrent events as was the case among RECAP-DM patients.
The major strength of the RECAP-DM study was the access to retrospective register data reflecting clinical practice. The estimated annual costs of health care thus mirrored the actual rates of resource utilization, without the interference of protocol-driven items. A large number of patients were included in the study because of participation by the majority of primary care centres at Uppsala and the panel data approach allowed for inclusion of episodes of AMI and stroke occurring over the course of the full 5-year period between 2000 and 2004.
It should be noted that no distinction was made between nonfatal and fatal AMIs and strokes in the regression models, as mortality data were not available for the entire study period (only until 2003). Patterns of resource use are likely to differ between these two types of events. Furthermore, only cases of AMI and stroke appearing in the Inpatient Register were tracked, thus nonhospitalized cases were not captured. Data from the Causes of Death Register for the years 2000-2003 provided an indication of the proportion of patients suffering fatal events who do not undergo hospitalization, showing that only 46% (91 out of 198) of RECAP-DM patients for which AMI was recorded as an underlying cause of death had an earlier record of an AMI-related hospitalization in the Inpatient Register. For study patients with stroke recorded as an underlying cause of death, 62% (69 out of 111) had records of an earlier stroke-related hospitalization. Clearly, the health care costs associated with nonhospitalized cases of AMI and stroke are substantially lower than the costs we report for hospitalized events.
We did not distinguish patients with several AMIs or several strokes during the course of a year from those suffering a single event. With regard to patients suffering both an AMI and a stroke during the course of a year, they were limited in number (first events: n = 28; first or recurrent events: n = 42). Health care costs predicted for this patient group using the reported coefficients will be very high because of the assumption of a multiplicative effect of AMI and stroke on costs and need further validation.
Any regression analysis evaluating the effect of individual predictors on an outcome of interest should deal with confounders, that is, factors associated with both the predictor and the outcome [24] . The panel data regression model we developed controlled for the effect of age, sex, amputation, renal failure, heart failure and diabetic eye disease on health care costs. The possibility, however, remains that the effect of AMI and stroke on costs is confounded by unrecognized or immeasurable
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factors. Diabetes is associated with other complications that contribute to the consumption of health care resources, such as foot ulcers and recurrent infections. One potential confounder for which data were lacking was diabetes duration, which is positively associated with the risk of AMI and stroke as well as health care costs because of the progressive nature of type 2 diabetes.
Recent studies have estimated the cost of AMI and stroke related to hospital admission in different countries in Europe [25, 26] , but the health care costs we report include all inpatient care (initial admission and follow-up hospitalizations), outpatient care, dialysis and drugs. This extended scope and the fact that costs of the average type 2 diabetic patient were estimated for the year of the event and subsequent years entails results of great use in health economic models. Unfortunately, data on sick leave and early unemployment were not available and the impact of an AMI and stroke on indirect costs could hence not be incorporated. A recent study in Denmark found that AMI was associated with a significant loss of income in men but not women in the year following disease [27] . In Finland, 38% of men and 40% of women of working age having suffered an MI have been found to receive disability pension 2 years after the event [28] .
In conclusion, our results confirm the substantial impact of AMI and stroke on costs in patients with type 2 diabetes. The reported estimates provide important input to economic evaluations of therapies in type 2 diabetes in Sweden.
